SPEAKERS
Precision therapies are reshaping the future of medicine and with them, the commercialization playbook.
Biopharma companies now have the opportunity to design leaner, smarter launch strategies tailored to the unique demands of targeted therapies. Join us to explore how Diaceutics’ new model for Precision Commercialization delivers a true partnership, purpose-built for the complexity of precision medicine.
Hear firsthand from Sarah Kurz, President & COO of Partner Therapeutics, as she shares her experience collaborating with Diaceutics to bring this innovative approach to life.
KEY LEARNINGS
Discover how you can design more agile and cost-effective launch models tailored to the specific demands of precision therapies
Navigating Precision Commercialization
Partnering for Success in Rare & Precision Therapies
Rebecca Fryer, Sarah Kurz & Peter Finlayson
18th November
11AM ET
ABOUT US
At Diaceutics we believe that every patient should have access to the right treatment at the right time to positively impact their disease outcome, and we are committed to solving commercialization challenges.
We provide the world's leading pharma and biotech companies with an end-to-end commercialization solution for the launch of precision medicine through our platform
DXRX - The Diagnostic Network®
Copyright © 2024, Diaceutics. All rights reserved
Understand how Diaceutics’ Precision Commercialization model fosters deep collaboration between stakeholders to streamline execution.
Gain insights into how proprietary clinical data and real-time engagement tools can inform decision-making and accelerate market adoption.
Rebecca Fryer
Head of Commercial Partnerships, Diaceutics
GUEST SPEAKERS
WITH
Sarah Kurz
President and Chief Operating Officer, Partner Therapeutics
Vice President, Marketing, Partner Therapeutics
Peter Finlayson
Watch our latest
WEBINAR
on demand
SUBMIT YOUR DETAILS TO WATCH THE RECORDING